Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: Demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life

Cancer

Volumn 113, Issue 10, 2008, Pages 2704-2713

  Elting, Linda S ^a   Keefe, Dorothy M ^b   Sonis, Stephen T ^c,d   Garden, Adam S ^a   Spijkervet, F K L ^e   Barasch, Andrei ^f   Tishler, Roy B ^c,d   Canty, Thomas P ^g   Kudrimoti, Mahesh K ^h   Vera Llonch, Montserrat ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Arizona Oncology Services   (United States)

^h UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

ⁱ POLICY ANALYSIS INC PAI   (United States)

Author keywords

Head and neck cancer; Mucositis; Patient reported outcomes; Quality of life; Radiation therapy

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR;

ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; COST OF ILLNESS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY; STOMATITIS;

EID: 55849123273     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23898     Document Type: Article

References (29)

1. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995-2025.
2. Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329-336.
3. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253-262.
4. Bentzen SM, Saunders MI, Dische S, et al. Radiotheraphyrelated early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol. 2001;60:123-135.
5. Stokman MA, Sonis ST, Dijkstra PV, et al. Assessment of oral mucositis in clinical trials: impact of training on evaluations in a multi-centre trial. Eur J Cancer. 2005;41:1735-1738.
6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-1715.
7. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxil in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-1704.
8. Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006;37:393-401.
9. Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer. 2007;109:1914-1922.
10. Murphy BA, Gilbert J, Cmelak A, et al. Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol. 2007;5:807-822.
11. Duncan GG, Epstein JB, Tu D, et al; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005;27:421-428.
12. Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and cost of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:110-120.
13. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stemcell transplantation setting. J Clin Oncol. 2006;24:5186-5193.
14. Cella DF, Tulsky DS, Gary G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol. 1993;11: 570-579.
15. Bonomi AE, Cella DE, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996;5:309-320.
16. Lai JS, Cella D, Chang CH, et al. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create and store a core item back from the FACIT Fatigue Scale. Qual Life Res. 2003;12:485-501.
17. Brucker PS, Yost K, Cashy J, et al. General population of cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005; 28:192-211.
18. Brucker PS, Yost K, Cash J, et al. Normative reference values for the FACT-G. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System Manual. Chicago, IL: Evanston Northwestern Healthcare. Version 4, 2005.
19. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse events? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22: 3485-3490.
20. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004;59:43-50,
21. Yao M, Karnell LH, Funk GF, et al. Health-related qualityof-life outcomes after IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1354-1360.
22. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:966-974.
23. Rose-Ped AM, Bellm LA, Epstein JB, et al. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 2002;25:461-467.
24. Peterman A, Cella D, Glandon D, et al. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr. 2001;29:45-51.
25. Cella D, Hahn EA, Dineen K. Meaningful change in cancerspecific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11:207-221.
26. Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distributionbased estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005;8:117-127.
27. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related qualify of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39:335-345.
28. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales. J Pain Symptom Manage. 2002;24:547-561.
29. Eton D, Yost K. Minimally Important Differences on the Functional Assessment of Chronic Illness Therapy Instruments. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System Manual. Chicago, IL: Evanston Northwestern Healthcare, Version 4, 2005.